Extension Study of Carvedilol RCT Study

• Status: Recruiting
• Trial end date: 2024-10-30
• Target enrollment: 0
• Participant gender: All

Summary

Patients who have completed 2-years treatment in RCT Study of carvedilol will receive another 2-years extension therapy, aiming to investigate the long-term efficacy of carvedilol for the prevention of esophageal varices in treated HBV cirrhotic patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Friendship Hospital
• Treatments: Carvedilol

Criteria

Inclusion Criteria:

• Subjects who completed the 2-year RCT study of carvedilol in HBV cirrhotic patients with anti-viral therapy;

• Subjects who are willing to participate the extension study.

Exclusion Criteria:

• Subjects who refused to receive 2-year EGD examination during the previous RCT study;

• Subjects who could not compliance with the protocol judged by investigators;

• Subjects who are not suitable for the study judged by investigators.